Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study

Documenti analoghi

• Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine
  di: Anna de Dios, et al.
  Pubblicazione: (2024)
• Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real‐life multicenter study
  di: Julia Peris‐Subiza, et al.
  Pubblicazione: (2025)
• Response to: Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays
  di: Alicia Alpuente, et al.
  Pubblicazione: (2026)
• Evaluation of the effectiveness and safety of anti‐CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO ‐ CGRP study
  di: María Clara García‐Castillo, et al.
  Pubblicazione: (2026)
• Letter to the Editor regarding “Persistence, effectiveness, and tolerability of anti‐calcitonin gene‐related peptide monoclonal antibodies in patients with chronic migraine”
  di: Joaquín Borrás‐Blasco, et al.
  Pubblicazione: (2025)